Plant-Derived Natural Compounds for the Treatment of Amyotrophic Lateral Sclerosis: An Update

Curr Neuropharmacol. 2022;20(1):179-193. doi: 10.2174/1570159X19666210428120514.

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is a motor neuron disease (MND) that typically causes death within 3-5 years after diagnosis. Regardless of the substantial scientific knowledge accrued more than a century ago, truly effective therapeutic strategies remain distant. Various conventional drugs are being used but are having several adverse effects.

Objective/aim: The current study aims to thoroughly review plant-derived compounds with welldefined ALS activities and their structure-activity relationships. Moreover, the review also focuses on complex genetics, clinical trials, and the use of natural products that might decrypt the future and novel therapeutics in ALS.

Methods: The collection of data for the compilation of this review work was searched in PubMed Scopus, Google Scholar, and Science Direct.

Results: Results showed that phytochemicals like-Ginkgolides, Protopanaxatriol, Genistein, epigallocatechingallate, resveratrol, cassoside, and others possess Amyotrophic lateral sclerosis (ALS) activity by various mechanisms Conclusion: These plant-derived compounds may be considered as supplements for conventional (ALS). Moreover, further preclinical and clinical studies are required to understand the structureactivity relationships, metabolism, absorption, and mechanisms of plant-derived natural agents.

Keywords: CNS disorders; Plant-derived products; SAR; SOD1 mutations; Therapeutic effects; clinical trials.

Publication types

  • Review

MeSH terms

  • Amyotrophic Lateral Sclerosis* / drug therapy
  • Humans
  • Motor Neuron Disease*